Australia Announces A “Fairer” Orphan Drugs Program, With New Eligibility And Validity Criteria
Executive Summary
New orphan drug designations under Australia’s reformed program will lapse after six months, although there is a 12-month transitional period for existing designations.
You may also be interested in...
Australian Orphan Fee Waivers To Expire As Transition Period Ends
The transition period for Australia’s new orphan drug program is coming to an end, and sponsors may need to take action if they want to keep their orphan status - and fee waivers - beyond the end of June.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.